Original antigenic sin describes how the immune system’s first exposure to a virus shapes responses to later, related strains. The concept was first described by Thomas Francis Jr. at the University of Michigan in 1960 and is often discussed today under the broader term immune imprinting. Researchers such as Florian Krammer at the Icahn School of Medicine at Mount Sinai have documented how prior exposures bias antibody specificity and recall responses after vaccination.
Mechanism
At the cellular level the bias arises because memory B cells and long-lived plasma cells generated by the first exposure are primed to recognize specific viral epitopes. When a person encounters a drifted strain or receives an updated vaccine, those existing memory cells can be reactivated preferentially, producing antibodies targeted to the original epitopes rather than novel antigenic sites. This effect is influenced by antigenic distance between strains and the relative abundance of cross-reactive versus strain-specific epitopes. In some cases the recalled response provides partial cross-protection; in others it limits the generation of new, strain-specific antibodies.
Consequences for vaccine effectiveness
Original antigenic sin can reduce measured vaccine effectiveness when the vaccine or circulating strain has changed enough that protective immunity requires responses to new epitopes. Studies of seasonal influenza show birth-cohort differences in susceptibility because first-exposure strains differed geographically and temporally, creating population-level imprinting patterns. The result is that a vaccine update may elicit robust antibody titers that nonetheless target familiar epitopes and fail to neutralize the contemporary virus efficiently. Conversely, imprinting can also explain why some individuals experience broader protection against related strains after early-life exposure that targeted conserved regions.
Implications and nuances
Practical implications include the need to design vaccines that either focus immune responses on conserved sites or present antigens in ways that favor naïve B cell activation over recall. Vaccine strategies under investigation aim for broadly neutralizing or universal vaccines to overcome imprinting limits. Cultural and territorial factors matter because circulating strains and vaccination policies differ by region, so population-level imprinting patterns vary between countries and age groups. Clinically significant effects therefore depend on complex interactions among host history, viral evolution, and vaccine formulation rather than a single deterministic rule.